ACTIVE

Hirundo Biosciences

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result-13,7 M €-987,6 %over 1 year

Revenue0 €-100,0 %over 1 year

Equity-548,2 k €-130,6 %over 1 year

Workforce12,2 ETP+351,9 %over 1 year

Identity

Source · BCE/KBO

Hirundo Biosciences is a Public limited company incorporated in 2017. Its main activity is: Buying and selling of own real estate. Its registered office is in Liège. It employs on average 12,2 ETP workers (FTE).

Legal situation: Normal situation
BCE/KBO no. / VAT: BE 0681.855.065
Incorporation: 28/09/2017
Legal form: Public limited company
Registered office: Boulevard de Patience et Beaujonc 3
4000 Liège · WallonieSee on map
Contributed capital: 1 468 649,92 €
Latest accounts: 31/12/2025
Average workforce: 12,2 ETP

Activities (NACE)

68100Buying and selling of own real estate· main 68110Buying and selling of own real estate 72109Research and experimental development on natural sciences and engineering 72190Other research and experimental development on natural sciences and engineering 72109Research and experimental development on natural sciences and engineering 72190Other research and experimental development on natural sciences and engineering

Joint committees (1)

Financials

Source · NBB, 8 filings

Trend over 8 financial years

	2025		2024		2023		2022		2021
Income statement
Revenue	0 €	-100%	277,7 k €		–		–		–
EBITDA	-4,1 M €	-4632%	-86,2 k €	-117%	498,6 k €	+254%	140,8 k €	-80.8%	733,3 k €
Operating result	-8,7 M €	-594%	-1,3 M €	-207%	-409,5 k €	+59.0%	-998,6 k €	-380%	-208,1 k €
Net result	-13,7 M €	-988%	-1,3 M €	-263%	-347,1 k €	+66.9%	-1 M €	-398%	-210,8 k €
Balance sheet
Equity	-548,2 k €	-131%	1,8 M €	-41.3%	3,1 M €	-10.2%	3,4 M €	-23.6%	4,4 M €
Total assets	3,4 M €	-50.6%	6,9 M €	+17.9%	5,8 M €	-0.2%	5,9 M €	-1.6%	6 M €
Cash	–		–		74 k €	-66.4%	220,6 k €	-34.3%	335,9 k €
Debts	3,9 M €	-22.8%	5,1 M €	+106%	2,5 M €	+4.3%	2,4 M €	+68.1%	1,4 M €
Other
Workforce	12,2 ETP	+352%	2,7 ETP	+35.0%	2,0 ETP	-28.6%	2,8 ETP	-6.7%	3,0 ETP

Board of directors

Source · NBB, accounts to 31/12/2025

3 active · 9 ended

Active mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
András Kovács Lászlò	Director25/04/2025 → 06/06/2030
Istvàn Greiner	Director19/06/2024 → 06/06/2030
Péter Turek	Director19/06/2024 → 06/06/2030

Ended mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Lászlò András Kovács	Directorlisted until the 2024 accounts
Istvan Hamecz	Director19/06/2024 → 2024 accounts
ACCESS & PARTNERS0452.367.319Represented by Didier Malherbe	Director01/06/2023 → 2024 accounts

Other companies at this address

Boulevard de Patience et Beaujonc 3 4000 Liège

Company	CBE no.
Abscint● Active	0749.828.410
Aeroforge● Active	1044.274.185
AMPACIMON● Active	0827.990.317
Amyl Therapeutics● Active	0758.775.372
BECARV● Bankrupt	0840.777.885
BE.SPINE● Active	1013.110.857
CATALYA● Active	0727.648.171
CEFALY Technology● Active	0870.578.661
DERMAX● Active	0667.730.677
DIANOSIC● Active	1034.558.646
DW Cefaly Holding● Active	0725.837.241
EARTH ALIVE CLEAN TECHNOLOGIES BELGIUM● Active	1023.778.481
EXO Biologics● Active	0732.982.379
ExoXpert● Active	1003.807.666
EYED PHARMA● Active	0508.599.605
HolyFox Invest● Active	1010.693.181
Hyloris● Active	0669.738.676
Hyloris Developments● Active	0542.737.368
Hyloris Pharmaceuticals● Active	0674.494.151
Hyloris Therapeutics● Active	1025.029.385

Full financial information

Source · NBB

	2025	2024	2023	2022	2021	2020
Type of account	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	24/07/2026	08/08/2025	21/08/2024	26/07/2023	31/08/2022	09/08/2021
General meeting	04/06/2026	23/07/2025	06/06/2024	08/06/2023	02/06/2022	03/06/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 8 filings

Model	Closing	General meeting	Filed	Language	Document
Abridged model	31/12/2025	04/06/2026	24/07/2026	French	PDF
Abridged model	31/12/2024	23/07/2025	08/08/2025	French	PDF
Abridged model	31/12/2023	06/06/2024	21/08/2024	French	PDF
Abridged model	31/12/2022	08/06/2023	26/07/2023	French	PDF
Abridged model	31/12/2021	02/06/2022	31/08/2022	French	PDF
Abridged model	31/12/2020	03/06/2021	09/08/2021	French	PDF
Abridged model	31/12/2019	04/06/2020	03/08/2020	French	PDF
Micro model	31/12/2018	06/06/2019	04/07/2019	French	PDF

Indicative valuation

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

3 active · 9 ended

Active mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
András Kovács Lászlò	Director25/04/2025 → 06/06/2030
Istvàn Greiner	Director19/06/2024 → 06/06/2030
Péter Turek	Director19/06/2024 → 06/06/2030

Ended mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Lászlò András Kovács	Directorlisted until the 2024 accounts
Istvan Hamecz	Director19/06/2024 → 2024 accounts
ACCESS & PARTNERS0452.367.319Represented by Didier Malherbe	Director01/06/2023 → 2024 accounts

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette

Capital / shares30/09/2026
CAPITAL, ACTIONS, STATUTS (TRADUCTION, COORDINATION,
PDF
Other24/06/2026
DIVERS
PDF
Capital / shares26/01/2026
STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - CAPITAL, ACTIONS
PDF
Registered office15/12/2025
DIVERS - SIEGE SOCIAL
PDF
Mandates22/07/2025
STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - DENOMINATION - CAPITAL, ACTIONS
PDF
Mandates03/06/2025
DEMISSIONS, NOMINATIONS
PDF
Mandates24/04/2025
DEMISSIONS, NOMINATIONS
PDF
Mandates02/09/2024
CAPITAL, ACTIONS - DEMISSIONS, NOMINATIONS
PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

Source · CBE, NBB annual accounts

Year

Identity

Incorporation

Name

Registered office

Annual accounts

Filings8 filings

Mandates

András Kovács Lászlò

Istvàn Greiner

Péter Turek

Lászlò András Kovács

Istvan Hamecz

ACCESS & PARTNERS

TheClubDeal Capital Advisors

NOSHAQ PARTNERS

Elisabeth Picou

Dominique Surleraux

Didier MALHERBE

Louis DE THANHOFFER DE VOLCSEY

20172018201920202021202220232024202520262027202820292030

Hirundo BiosciencesB.C.I. PHARMA

Boulevard de Patience et Beaujonc 3, 4000 LiègeAvenue de l'Hôpital 11, 4000 Liège

Director

Managing director

Director

CurrentPlanned, not yet servedEndedAccounts filedToday

Registered offices

Source · NBB annual accounts, CBE

Registered address	Period	Source
Boulevard de Patience et Beaujonc 3, 4000 LiègeCurrent	accounts 2025	Accounts 2025 · 2026-00337166
Avenue de l'Hôpital 11, 4000 Liège	accounts 2021 → 2024	Accounts 2024 · 2025-00378116

Company names

Source · NBB annual accounts, CBE

Name	Period	Source
Hirundo BiosciencesCurrent	accounts 2024 → 2025	Accounts 2025 · 2026-00337166
B.C.I. PHARMA	accounts 2021 → 2023	Accounts 2023 · 2024-00355349

Events

2025
Annual accounts 2025-13,7 M €↓
2024
Annual accounts 2024-1,3 M €↓
2024
Name changeHirundo Biosciences
2023
Annual accounts 2023-347,1 k €↑
2022
Annual accounts 2022-1 M €↓
2021
Annual accounts 2021-210,8 k €↑
2020
Annual accounts 2020-463,3 k €↑
2019
Annual accounts 2019-1,2 M €↓
2018
Annual accounts 2018-720,2 k €
28/09/2017
IncorporationPublic limited company

Hirundo Biosciences

Overview

Identity

Financials

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline

Timeline

Registered offices

Company names

Events